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INTRODUCTION 
 The nervous system is more frequently affected by a genetic abnormality 
than any other organ system, probably because of large number of genes 
implicated in its development (an estimated one-third genes in the human 
genome).  Approximately one-third of all inherited diseases are neurologic to 
some extent; if one adds the inherited diseases affecting the musculature, skeleton, 
eye and ear, the number rises to 80 to 90 percent. 
 Among the list of inherited diseases affecting the nervous system which are 
often not curable one potentially treatable inherited disease affecting the nervous 
system is Wilson disease.   
 Wilson disease is transmitted as an autosomal recessive trait, and the 
abnormal gene resides on chromosome 13, in the region of 13q14.  One of the 
curious aspects of the disease is the multitude of mutations affecting ATP7B gene.  
The genetic defect gives rise to two fundamental disturbances of copper 
metabolism – a reduced rate of incorporation of copper into ceruloplasmin and a 
reduction in biliary excretion of copper into ceruloplasmin. The deposition of 
copper in tissues is the cause of virtually all the manifestations of the disease – 
cirrhosis, hemolytic anaemia, renal tubular changes, Kayser-Fleischer rings and, in 
all likelihood, the cerebral damage. 
 Neurological manifestations are second most common form of presentation 
and are the predominant pattern seen in adults.  The onset of neurologic symptoms 
is usually in the second and less often in the third decade.  The first neurological 
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manifestations are most often extrapyramidal with a proclivity to affect the 
oropharyngeal musculature.  The typical presentations are tremor of a limb or of 
the head and generalized slowness of movement or slowness of movements of the 
tongue, lips , pharynx, larynx, and jaws, resulting in dysarthria, dysphagia and 
hoarsness.  As the disease progresses, the classic syndrome with features of 
parkinsonism develops.   
 The disease in advanced stages poses a considerable degree of neurological 
impairment and disability.  As the disease affects the young and productive age 
group of the population it poses a huge burden both for the family and the 
community as a whole both on social and economic aspects. 
 Newer advances in medicine has brought a considerable degree of relief 
such that the disease can be diagnosed at an early stage and potential treatment 
options are available to prevent and reduce the morbidity caused by the 
neurological disease.  But still the disease remains undiagnosed most often in a 
population like ours where early hepatic manifestation of Wilson are 
underrecognised and often left undiagnosed to present later with neurological 
manifestations which are all not completely reversible. 
 Therefore considerable improvements have to be made to study the 
epidemiology of the disease in our community, develop cost effective methods to 
diagnose and provide treatment. Research has to be initiated to know the genetics 
of the Indian Wilson which present at an earlier age group when compared with 
the western world. 
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 In view of the early occurrence and the multiple modes of presentation, 
with special preference to nervous system an attempt has been made to pick up 
Wilson disease through nervous system. 
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AIMS OF THE STUDY 
 
1) To find out the prevalence of Wilson disease among those attending 
neurology clinic 
2) To analyze their socio demographic aspects  
3) To study the pattern of presentation, analyze the symptomatology 
and elicit the familial nature of the disease. 
4) To interpret and compare the laboratory investigation with the 
clinical picture of the patients. 
5) To assess the clinical response to treatment and to study the 
complications (if any) out of the treatment in the short term. 
6) To elicit selected social aspects of the disease.  
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REVIEW OF LITERATURE 
WILSON DISEASE 
 
INTRODUCTION 
Wilson disease (hepatolenticular degeneration) is an autosomal recessive 
disorder characterized by degenerative changes in the brain, liver disease, and 
Kayser-Fleischer ring in the cornea leading on to varying patterns of hepatic, 
neurological and psychiatric symptoms.  Because effective treatment is available 
early diagnosis has to be made. 
 
HISTORY  
Wilson disease was first described in 1912 by Kinnear Wilson as 
‘progressive lenticular degeneration’, a familial, lethal neurologic disease 
accompanied by chronic liver disease leading to cirrhosis.¹  The association of 
corneal copper deposits with this disorder was later made by Kayser and 
Fleischer.2  Over the next several decades the role of copper in the pathogenesis of 
Wilson disease was established, and the pattern of inheritance was determined to 
be autosomal recessive.³ 
In 1993 the abnormal gene in Wilson disease was identified.4-7  The gene, 
ATP7B, sometimes also referred to as “WND”, encodes a metal transporting        
P-type ATPase, which is expressed mainly in hepatocytes and functions in the 
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transmembrane transport of copper.  Absent or reduced function of ATP7B protein 
leads to decreased hepatocellular excretion of copper into bile. This results in 
hepatic copper accumulation and injury. Eventually copper is released into the 
bloodstream and deposited in various other organs, notably the brain, kidneys and 
cornea.  
Wilson disease was one of the first liver diseases for which effective 
pharmacologic treatment was identified. The first chelating agent introduced in 
1951 for the treatment of Wilson disease was British anti-lewisite (BAL or 
dimercaptopropanol) .8-9 The identification and testing of an orally administered 
chelator, D-penicillamine, by John Walsh in 1956 revolutionized treatment of this 
disorder.10  
Other treatment modalities have since been identified, including use of zinc 
salts (Schouwink  in 1961 introduced zinc as an alternative to penicillamine) to 
block enteral copper absorption and orthotopic liver transplantation, which may be 
lifesaving and curative for this disorder. Over the years diagnostic advances have 
enabled more systematic screening of individuals suspected to have Wilson 
disease prior to their development of neurologic symptoms.  More recently, 
molecular diagnostic studies have made it feasible to define patterns of haplotypes 
or polymorphisms of DNA surrounding ATP7B, which are useful for identification 
of first-degree relatives of newly diagnosed patients. In some patients disease-
specific mutations on both alleles of chromosome 13 can be determined. 
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EPIDEMIOLOGY OF THE DISEASE 
The worldwide incidence rate is 10-30 million cases, with increased rates in 
areas of consanguinity. The heterozygote carrier rate is 1 case per 100 persons, 
corresponding to a gene frequency varying between 0.3-0.7 percent. The 
frequency ranges worldwide from 1 case per 30,000 populations in Japan, to 1 
case per 100,000 populations in Australia. It occurs in all races and is 
comparatively more common in Jews of east European origin, Arabs, Italians, 
Japanese, Chinese and Indians. 
GENETICS 
 The abnormal gene for Wilson disease is on chromosome 13; 
linkage studies have assigned the Wilson disease locus to chromosome 13 at 
q14.3-q21.1.  Wilson disease gene, like the Menkes disease gene encodes a     
1411-amino-acid copper-binding cation transporting P-type ATPase with 14 
domains—6 copper binding, 4 transmembrane, 1 phosphatase, 1 transduction,       
1 phosphorylation and 1 ATP binding. The Menkes and Wilson genes have 55% 
amino acid identity. The Menkes and Wilson ATPases utilize common 
biochemical mechanisms, but the tissue-specific expression differs. The Wilson 
disease gene is found predominantly in liver, kidney and placenta, and to a lesser 
extent, in heart, brain, lung, muscle and pancreas.  All copper-transporting 
ATPases have a histidine residue in the large cytoplasmic loop, adjacent to the 
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ATP binding domain. The histidine residue is essential for function and is the most 
common mutation in Wilson disease.   
The most common gene mutations are single base pair changes or frame-
shift mutations due to small deletions. Occasionally, splicing errors are seen.  
Mutations that completely destroy gene function are associated with an onset of 
disease symptoms as early as 2-3 yr of age, when Wilson disease may not 
typically be considered in the differential diagnosis. Milder mutations can be 
associated with neurologic symptoms or liver disease as late as 50 yr of age. 
Genetic testing may be helpful in diagnosing a patient's asymptomatic relatives but 
has not replaced the traditional laboratory studies because of the large number of 
mutations that have been identified (approximately 200). 
PATHOPHYSIOLOGY 
   The estimated total body copper content is 50-100 mg, with an average 
daily intake of 1-2 mg. Copper is an important component of several metabolic 
enzymes, including lysyl oxidase, cytochrome c oxidase, superoxide dismutase 
and dopamine beta-hydroxylase. Intestinal copper absorption and transport into 
hepatocytes is intact in Wilson disease. After copper reaches the hepatocyte, it is 
incorporated into copper-containing enzymes, including ceruloplasmin (α2 
globulin).  Excess copper may be rendered nontoxic by forming complexes with 
apo-metallothionein to produce copper-metallothionein, or it may be excreted into 
bile. 
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The ATPase affected by Wilson disease is predominantly in the liver and 
transports copper within the hepatocyte, thereby allowing the incorporation of 
copper into ceruloplasmin and subsequent excretion into the bile. This is the only 
significant pathway for copper removal. In Wilson disease, the processes of 
incorporation of copper into ceruloplasmin and excretion of excess copper into 
bile are impaired.  Excess hepatic copper is initially bound to metallothionein, but 
as this storage capacity is exceeded, liver damage begins as early as 3 years of age. 
Copper accumulation in the cytoplasm of hepatocytes results in cellular necrosis. 
The underlying mechanism of liver damage in Wilson disease is presumably 
oxidant injury to the hepatocyte mitochondria, which is the target organelle in 
copper-induced toxicity. Lipid peroxidation of the mitochondria resulting from 
copper overload leads to functional alterations. 
Defective copper incorporation into apoceruloplasmin leads to excess 
catabolism and low blood levels of ceruloplasmin. Serum copper levels are usually 
lower than normal because of low blood ceruloplasmin, which normally binds 
>90% of serum copper. As the disease progresses, non-ceruloplasmin serum 
copper ("free" copper) levels increase. The excess copper then collects in 
extrahepatic tissues, including the basal ganglia, kidney and the descement’s 
membrane of the cornea, to which it is toxic, primarily as a potent inhibitor of 
enzymatic processes. Ionic copper inhibits pyruvate oxidase in brain and ATPase 
in membranes, leading to decreased ATP-phosphocreatine and potassium content 
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of tissue. The glycolytic pathway and microsomal membrane ATPases are 
inhibited. 
Staging: The natural history of the disease may be considered in 4 stages, as 
follows:  
• Stage I - The initial period of accumulation of copper by hepatic binding 
sites 
• Stage II - The acute redistribution of copper within the liver and its release 
into the circulation 
• Stage III - The chronic accumulation of copper in the brain and other 
extrahepatic tissue, with progressive and eventually fatal disease 
• Stage IV - The achievement of copper balance with chronic chelation 
therapy. 
CLINICAL PRESENTATION 
 There are protean manifestations of the disease which may appear as early 
as 4 years of age or may be delayed until the fifth decade.  Wilson disease 
manifests as liver disease in children and adolescents, peaking at ages 10-13 years, 
and as neuropsychiatric illness in young adults aged 19-20 years. In India and 
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countries in the Far East, the hepatic presentation may occur much earlier, often in 
children only five or six years of age. 
Hepatic presentation 
 The type of the liver disease can be highly variable, ranging from 
asymptomatic with only biochemical abnormalities to fulminant hepatic failure. 
Children may be entirely asymptomatic, with hepatic enlargement or abnormal 
serum aminotransferases found only incidentally. Some patients have a brief 
clinical illness resembling an acute viral hepatitis, and others may present as 
clinically indistinguishable from autoimmune hepatitis. Some present with only 
biochemical abnormalities or histologic findings of steatosis on liver biopsy. Many 
patients present with signs of chronic liver disease and evidence of cirrhosis, either 
compensated or decompensated. Patients may present with isolated splenomegaly 
due to clinically inapparent cirrhosis with portal hypertension. Wilson disease may 
also present as fulminant hepatic failure with an associated Coombs-negative 
hemolytic anemia and acute renal failure. Fulminant presentation of Wilson 
disease is more common in females than males (4:1).  Some patients have 
transient episodes of jaundice, due to hemolysis. Low-grade hemolysis may be 
associated with Wilson disease when liver disease is not clinically evident.  
In one series hemolysis was a presenting feature in 25 out of 220 cases 
(12%); in these patients hemolysis occurred as a single acute episode, recurrently, 
or was low-grade and chronic.11 In a series of 283 Japanese cases of Wilson 
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disease, only 3 presented with acute hemolysis alone, but one quarter of the 
patients who presented with jaundice also had hemolysis.12  Patients diagnosed 
with Wilson disease who have a history of jaundice may have previously 
experienced an episode of hemolysis. Patients with apparent autoimmune hepatitis 
presenting in childhood, or in adults with a suspicion of autoimmune hepatitis that 
does not readily respond to therapy should be assessed carefully for Wilson 
disease because elevated serum immunoglobulins and detectable nonspecific 
autoantibodies may be found in both conditions. 13-15 
 Hepatic Wilson disease should be considered in the differential diagnosis 
of any unexplained chronic liver disease, especially in individuals younger than 40 
years. 
Neuropsychiatric presentation 
 Neurologic manifestations of Wilson disease typically present later than the 
liver disease, most often in the second decade of life, but they can present in 
childhood. Earlier subtle findings may appear in pediatric patients, including 
changes in behavior, deterioration in schoolwork or inability to perform activities 
requiring good hand-eye coordination. Handwriting may deteriorate, and cramped 
small handwriting, as in Parkinson disease (micrographia), may develop.  
Most patients who present with neuropsychiatric manifestations have 
cirrhosis, frequently asymptomatic. The most common presenting neurologic 
feature is asymmetric tremor, occurring in approximately half of individuals with 
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Wilson disease. The character of the tremor is variable and may be predominantly 
resting, postural or kinetic. 
Frequent early symptoms include difficulty in speaking, excessive 
salivation, ataxia, mask like facies, clumsiness with the hands and personality 
changes. 
Late manifestations (now rare because of earlier diagnosis and treatment) 
include dystonia, spasticity, grand mal seizures, rigidity and flexion contractures.   
Autonomic disturbances may include orthostatic hypotension and sweating 
abnormalities as well as bowel, bladder and sexual dysfunction. Memory loss, 
migraine-type headaches and seizures may occur. Patients have difficulties 
focusing on tasks, but cognition is not usually grossly impaired. Sensory 
abnormalities and muscular weakness are not features of the disease. Because of 
pseudobulbar palsy, transfer dysphagia may also occur, with a risk of aspiration, if 
severe.  
Walshe described 4 distinct diagnostic categories based on patients' major 
neurologic findings and it was published two decades ago.  The details are given 
below  
1) The parkinsonian patients (45%) were distinguished by paucity of 
expression and movement.  
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2) The pseudosclerotic patients (24%) had tremor resembling multiple 
sclerosis.  
3) The patients in the dystonic group (15%) were characterized by 
hypertonicity associated with abnormal limb movements.  
4) The patients in the choreic group (11%) were predominantly 
characterized by choreoathetoid abnormal movements associated with dystonia. 
 The psychiatric manifestations of Wilson disease have been frequently 
noted. In his original monograph Wilson described “psychical” symptoms in 8 out 
of his 12 cases; since then, many studies and case reports have described 
psychiatric symptoms or disorders in patients with Wilson disease. Scheinberg and 
Sternlieb went so far as to state that “almost every patient with clinically manifest 
Wilson disease suffers at some time during the course of his disease” with 
psychiatric problems.  
Psychiatric features include emotional lability, impulsiveness, disinhibition 
and self-injurious behavior. The reported percentage of patients with psychiatric 
symptoms as the presenting clinical feature is 10-20%. The range of psychiatric 
abnormalities associated with Wilson disease has been divided into 4 basic 
categories, as follows:  
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1) Behavioral  
2) Affective  
3) Schizophrenic like  
4) Cognitive 
Opthalmological manifestations 
Kayser-Fleischer rings are formed by the deposition of copper in Descemet 
membrane in the limbus of the cornea. The color may range from greenish gold to 
brown; when well developed, rings may be readily visible to the naked eye or with 
an ophthalmoscope set at +40. When not visible to the unaided eye, the rings may 
be identified using slit-lamp examination or gonioscopy. 
Kayser-Fleischer rings consist of electron-dense granules rich in copper and 
sulfur. The rings form bilaterally, initially appearing at the superior pole of the 
cornea, then the inferior pole, and, ultimately, circumferentially. 
Large series of patients with Wilson disease show that Kayser-Fleischer 
rings are present in only 50% to 62% of patients with mainly hepatic disease at the 
time of diagnosis.16-20    In children presenting with liver disease Kayser-Fleischer 
rings are usually absent. 21-23   Kayser-Fleischer rings are almost invariably present 
in patients with a neurologic presentation, but even in these patients they may not 
be found in 5%.24  Other ophthalmologic changes may be found. Sunflower 
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cataracts, also found by slit-lamp examination, represent deposits of copper in the 
lens.25  These typically do not obstruct vision.  Both Kayser-Fleischer rings and 
sunflower cataracts will gradually disappear with effective medical treatment or 
following liver transplantation, although the rate of disappearance does not 
correlate with resolution of clinical symptoms.26-27  The reappearance of either of 
these ophthalmologic findings in a medically treated patient in whom these had 
previously disappeared suggests noncompliance with therapy. 
Although Kayser-Fleischer rings are a useful diagnostic sign, they are no 
longer considered pathognomonic of Wilson disease unless accompanied by 
neurologic manifestations. They may also be observed in patients with chronic 
cholestatic disorders such as partial biliary atresia, primary biliary cirrhosis, 
primary sclerosing cholangitis, and cryptogenic cirrhosis. These diseases can 
usually be distinguished from Wilson disease on clinical grounds.  
Renal manifestations 
The Wilson disease gene is expressed in kidney tissue; therefore, any renal 
manifestations may be primary or secondary to release of copper from the liver. 
Clinically, patients may resemble those with Fanconi’s syndrome, demonstrating 
defective renal acidification and excess renal loss of amino acids, glucose, 
fructose, galactose, pentose, uric acid, phosphate and calcium. The frequency of 
renal manifestations is variable. 
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 Urolithiasis, found in up to 16% of patients with Wilson disease, may be 
the result of hypercalciuria or poor acidification. 
 Hematuria and nephrocalcinosis are reported, and proteinuria and 
peptiduria can occur both before treatment as part of the disease process and after 
therapy as adverse effects of D-penicillamine. 
Musculoskeletal manifestations 
Skeletal involvement is a common feature of Wilson disease, with more 
than half of patients exhibiting osteopenia on conventional radiologic examination.  
The arthropathy of Wilson disease is a degenerative process that resembles 
premature osteoarthritis. Symptomatic joint disease, which occurs in 20-50% of 
patients, usually arises late in the course of the disease, frequently after age 20 
years. The arthropathy generally involves the spine and large appendicular joints 
such as knees, wrists and hips. Osteochondritis dissecans, chondromalacia patellae 
and chondrocalcinosis have also been described. 
Other manifestations 
 Some female patients have repeated spontaneous abortions, and most 
become amenorrheic prior to diagnosis.   
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 Electrocardiographic and other cardiac abnormalities have been reported 
but are not common.  Endocrinological abnormalities in the form of 
hypoparathyroidism can occur. 
Rare case reports of Wilson disease presenting with olfactory dysfunction28, 
severe generalized myoclonus, encephalopathy like manifestations, hypokalaemic 
periodic paralysis due to RTA,29 mixed polyneuropathy,30 etc have been described. 
DIAGNOSIS 31-38 
The presence of Kayser-Fleischer rings and ceruloplasmin levels of less 
than 20 mg/dL in a patient with neurologic signs or symptoms suggest the 
diagnosis of Wilson disease. If a patient is asymptomatic/ exhibits isolated liver 
disease, and lacks corneal rings, the coexistence of a hepatic copper concentration 
of more than 250 µg/g of dry weight and a low serum ceruloplasmin level is 
sufficient to establish a diagnosis. 
Serum ceruloplasmin 
• Serum ceruloplasmin levels are low in newborns and gradually rise within 
the first 2 years of life. Approximately 90% of all patients with Wilson 
disease have ceruloplasmin levels of less than 20 mg/dL (reference range, 
20-40 mg/dL). 
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• Ceruloplasmin is an acute phase reactant and may be increased in response 
to hepatic inflammation, pregnancy, estrogen use or infection. 
• Falsely low ceruloplasmin levels may be observed in any protein deficiency 
state, including nephrotic syndrome, malabsorption, protein-losing 
enteropathy and malnutrition. Ceruloplasmin levels may also be decreased 
in 10-20% of WD gene heterozygotes, who do not develop Wilson disease 
and do not require treatment. 
• The method used by the laboratory (the oxidative assay or nephlometric 
assay) may also affect the results of ceruloplasmin measurement. 
Urinary copper excretion 
• The urinary copper excretion rate is greater than 100 mg/d (reference range, 
<40 mg/d) in most patients with symptomatic Wilson disease. The rate may 
also be elevated in other cholestatic liver diseases.  
• Both the sensitivity and specificity of this test are suboptimal for use as a 
screening test; however, it may be useful to confirm the diagnosis and to 
evaluate the response to chelation therapy. 
Hepatic copper concentration 
• This test is regarded as the criterion standard for diagnosis of Wilson 
disease. 
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• A liver biopsy with sufficient tissue reveals levels of more than 250 µg/g of 
dry weight even in asymptomatic patients. Special collection vials are 
available to help avoid contamination. 
• A normal hepatic copper concentration (reference range, 15-55 µg/g) 
effectively excludes the diagnosis of untreated Wilson disease. An elevated 
hepatic copper concentration may be found in other chronic hepatic (mostly 
cholestatic) disorders. 
Radiolabeled copper 
• Radiolabeled copper testing directly assays hepatic copper metabolism. 
Blood is collected at 1, 2, 4, 24, and 48 hours after oral ingestion of 
radiolabeled copper (64Cu or 67Cu) for radioactivity in serum. In all 
individuals, radioactivity promptly appears after absorption, followed by 
hepatic clearance. In healthy people, reappearance of the radioactivity in 
serum occurs as the labeled copper is incorporated into newly synthesized 
ceruloplasmin and released into the circulation. 
• Heterozygotes exhibit a slow lower-level reappearance of radioactivity 
rather than the continued fall in radioactivity in those with Wilson disease, 
but there may be considerable overlap between the two. Patients with 
Wilson disease, even those with normal ceruloplasmin levels, do not exhibit 
the secondary rise in radioactivity. 
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Genetic diagnosis 
Linkage analysis has been used in family studies for presymptomatic 
testing; however, the multiplicity of mutations (>200 mutations) of ATP7B have 
been identified that require screening in individuals without affected family 
members is large, making such analysis impractical. Therefore, the use of 
molecular testing is currently limited to screening of family members for an 
identified mutation detected in the index patient. 
Imaging Studies:  
• Cranial CT scan 
o The cranial lesions observed on CT scan are typically bilateral and 
are classified into 2 general categories, i.e., (1) well-defined, slit 
like, low-attenuation foci involving the basal ganglia, particularly 
the putamen and (2) larger regions of low attenuation in the basal 
ganglia, thalamus or dentate nucleus. 
o Widening of the frontal horns of the lateral ventricles and diffuse 
cerebral and cerebellar atrophy, which correlate histologically with 
widespread neuronal loss, have also been described. 
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• Brain MRI 
o MRI of the brain appears to be more sensitive than CT scanning in 
detecting early lesions of Wilson disease. 
o MRI studies have identified focal abnormalities in the white matter, 
pons and deep cerebellar nuclei. These lesions, measuring 3-15 mm 
in diameter, are typically bilateral, appearing with low signal 
intensity on T1-weighted images and with high signal intensity on 
T2-weighted images, representing cell loss and gliosis. Other studies 
describe decreased signal intensity in the putamen and other parts of 
the basal ganglia, which may represent either copper or iron ferritin 
deposition. 
o A characteristic "face of the giant panda" sign has been described, 
formed by high signal intensity in the tegmentum (except for the red 
nucleus), preserved signal intensity of the lateral portion of the pars 
reticulata of the substantia nigra, and hypointensity of the superior 
colliculus. 
• Positron emission tomography scan 
o Positron emission tomography (PET) scan reveals a significantly 
reduced regional cerebral metabolic rate of glucose consumption in 
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the cerebellum, striatum, and, to a lesser extent, in the cortex and 
thalamus. 
o PET analyses of patients with Wilson’s disease have also 
demonstrated a marked reduction in the activity of dopa-
decarboxylase, indicative of impaired function of the nigrostriatal 
dopaminergic pathway. 
o These abnormalities improve with chelation therapy, indicating a 
reversible component of striatal neuron injury. 
Abdominal imaging: CT scan, MRI, ultrasound, and nuclear medicine studies of 
the liver have been uninformative, with findings neither specific nor sensitive for 
Wilson’s disease.  
• Electron microscopy 
o Electron microscopic studies on ultra thin sections reveal numerous 
electron-dense lysosomes and residual bodies. 
o The elemental analysis in transmission electron microscopy with 
electron energy loss spectroscopy, and in scanning electron 
microscopy with energy dispersive x-ray analysis, shows copper-
specific signals of electron-dense accumulations inside these dark 
lysosomes and residual bodies. 
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o The electron microscopic detection of copper-containing hepatocytic 
lysosomes is helpful for the diagnosis of early stages of Wilson 
disease in addition to the quantification of hepatic copper by atomic 
absorption spectrophotometry. 
Other Tests:  
• Resting ECG abnormalities include left ventricular or biventricular 
hypertrophy, early repolarization, ST segment depression, T-wave 
inversion and various arrhythmias. 
Procedures:  
In the absence of Kayser-Fleischer rings or neurologic abnormalities, a liver 
biopsy for quantitative copper determination is essential to establish the diagnosis 
of Wilson’s disease  
Histological Findings:  
Hepatic  
• The earliest changes detectable with light microscopy include glycogen 
deposition in the nuclei of periportal hepatocytes and moderate fatty 
infiltration. The lipid droplets, which are composed of triglycerides, 
progressively increase in number and size, sometimes resembling the 
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steatosis induced by ethanol. Hepatocyte mitochondria typically exhibit 
heterogeneity in size and shape, with increased matrix density, separation 
of the normally apposed inner and outer mitochondrial membranes, 
widened intercristal spaces, and an array of vacuolated and crystalline 
inclusions within the matrix. With progression of disease, copper protein is 
sequestered in lysosomes and is visible as electron-dense pericanalicular 
granules.  
• Despite consistently elevated hepatic copper levels in patients with Wilson 
disease, histochemical staining of liver biopsy specimens for copper is of 
little diagnostic value. Early in the disease, copper distribution is primarily 
cytoplasmic and is not readily apparent with rhodamine or rubeanic acid 
staining.  
• The rate of progression of the liver histology from fatty infiltration to 
cirrhosis is variable, although it tends to occur by one of two general 
processes, either with or without hepatic inflammation. The histologic 
picture may be histologically indistinguishable from that of chronic active 
hepatitis. Pathologic features include mononuclear cell infiltrates, which 
consist mainly of lymphocytes and plasma cells, piecemeal necrosis 
extending beyond the limiting plate, parenchymal collapse, bridging hepatic 
necrosis, and fibrosis. The histologic pattern is one of a macronodular or 
mixed micro-macronodular cirrhosis, with fibrous septa (containing 
predominantly types I and III collagen), bile ductule proliferation, and 
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variable septal round cell infiltration. Hepatocytes at the periphery of the 
nodules frequently contain Mallory hyaline.  
• One proposed mechanism implicates copper as the inducer of fibrogenesis. 
Interestingly, hepatocellular carcinoma is exceedingly rare in patients with 
Wilson’s disease compared to patients with hemochromatosis. This may be 
attributable to the significantly shortened life expectancy in untreated 
patients, which does not allow time for carcinoma to develop. An 
increasing number of case reports suggest that the incidence will likely 
increase with improved survival. It has been proposed that the diminished 
cancer risk is due to the relatively low inflammatory component in the 
pathogenesis of Wilson’s disease.  
Neurologic  
• Observed gross anatomic changes include degeneration and cavitation, 
primarily involving the putamen, globus pallidus, caudate nucleus and 
thalamus.  
• Little correlation has been observed between the degree of neurologic 
impairment and the neuropathologic findings. The affected areas of the 
brain do not possess higher copper concentrations than the unaffected 
portions.  
 27
In 2001 at the 8th international conference on Wilson disease and Menkes 
disease a scoring system for the diagnosis of Wilson disease was discussed39. The 
aim was to provide objective criteria with high sensitivity and specificity for the 
diagnosis of Wilson disease. A combination of clinical and biochemical tests with 
a score ranging from 0 to 4 for each test were developed. 
The patients with a total score of at least 4 were diagnosed with Wilson 
disease. The patients with a total score of two to three were considered as "likely 
to have Wilson's disease, yet more investigations had to be performed". The 
diagnosis of Wilson's disease was judged to be improbable for scores between zero 
and one. With respect to molecular analysis, it should be noted that more than 200 
different mutations have been identified. It has been difficult to devise a simple 
genetic screening test for the disease. 
  In order to test this scoring system, 143 children with chronic liver 
disease, aged at least 5 years, were reviewed. All patients had urinary copper 
assessments and a liver biopsy as part of the diagnostic work up.  
Fifty patients with Wilson disease had a score >= 4 (true positives). A total 
of 85 true negatives with a score of either 2-3 (40 children) or < 1 (45 children) 
were observed. Only 3 patients with Wilson disease had a score of 2 to 3 (false 
negatives), while 5 non Wilson disease patients had a score of at least 4 (false 
positives). Both sensitivity and specificity of this scoring system was higher than 
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94%. In addition, positive predictive value and negative predictive values were 
higher than 90% (90.9% and 96.59% respectively). 
Table 1: Scoring system for the diagnosis of Wilson disease 
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Table 2 : Scoring system for the diagnosis of Wilson disease 
 
TREATMENT40 
 Penicillamine was previously the primary anticopper treatment but now 
plays a minor role because of its toxicity and because it worsens existing 
neurologic disease if used as initial therapy. If penicillamine is given, it should 
always be accompanied by 25 mg/d of pyridoxine. Trientine is a less toxic chelator 
and has largely supplanted penicillamine.  
For patients with hepatitis or cirrhosis, without evidence of hepatic 
decompensation other than a mildly elevated bilirubin level and without 
neurologic or psychiatric symptoms from Wilson’s disease, zinc is the therapy of 
choice, although some advocate therapy with trientene. Zinc has proven efficacy 
in Wilson disease and is essentially nontoxic. It produces a negative copper 
balance by blocking intestinal absorption of copper, and it induces hepatic 
metallothionein synthesis, which sequesters additional toxic copper.                   
All presymptomatic patients should be treated prophylactically, since the disease 
is close to 100% penetrant.  
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The first step in evaluating patients presenting with hepatic decompensation 
is to establish disease severity, which can be estimated using the Nazer prognostic 
index. Patients with scores = 6 can usually be managed with medical therapy. 
Patients with scores = 10 should be considered immediately for liver 
transplantation, and those with scores between 7 and 9 require clinical judgment as 
to whether to recommend transplantation or medical therapy. A combination of 
trientine and zinc has been used to treat patients with Nazer scores as high as 9, 
but such patients should be watched carefully for indications of hepatic 
deterioration, which mandates transplantation.  
For initial medical therapy of patients with hepatic decompensation, a 
chelator (trientine is preferred) plus zinc is recommended. Zinc should not, 
however, be ingested simultaneously with trientine, as it will chelate zinc and form 
therapeutically ineffective complexes; the two drugs should be separated by at 
least 1 hr. Hepatic transplantation is necessary for patients with severe hepatic 
decompensation.  
For initial neurologic therapy, tetrathiomolybdate is emerging as the drug 
of choice because of its rapid action, preservation of neurologic function, and low 
toxicity. However, until tetrathiomolybdate is commercially available, trientine 
and zinc are recommended for 8 weeks, at which time the trientine can be stopped, 
and zinc continued for maintenance therapy. Although hepatic transplantation may 
improve neurologic symptoms, it does so only by removing copper, which can be 
done more safely and inexpensively with anticopper drugs.  
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Table 3: Profile of drugs used in the treatment of Wilson disease 
DRUG MODE OF 
ACTION 
NEUROLOGICAL 
DETORIATION? 
SIDE EFFECTS COMMENTS
D-
penicillamine 
General 
chelator; 
induces 
cupriuria 
10% to 50% during 
initial phase of 
treatment 
Fever, rash, 
proteinuria, 
aplastic anaemia, 
leucopenia, 
thrombocytopenia, 
nephritic 
syndrome, 
degenerative 
changes in skin, 
elastosis perforans 
serpiginosa, 
serous retinitis, 
hepatotoxicity, 
Reduced dose 
for surgery to 
promote 
wound 
healing & 
during 
pregnancy 
Trientine General 
chelator; 
induces 
cupriuria 
Occasionally during 
initial phase of 
treatment 
Gastritis, aplastic 
anaemia rare, 
sideroblastic 
anaemia,  
Reduced dose 
during 
surgery to 
promote 
wound 
healing and 
during 
pregnancy 
Zinc Metallothionein 
inducer; blocks 
intestinal 
absorption of 
copper 
During initial phase 
of treatment 
Gastritis; 
biochemical 
pancreatitis, zinc 
accumulation, 
possible changes 
in immune 
function 
No dose 
reduction for 
surgery or 
pregnancy 
Tetrathio-
molybdate 
General 
chelator; blocks 
copper 
absorption, 
induces 
intestinal and 
urinary copper 
loss 
Reports of only rare 
neurologic 
detoriation during 
initial treatment 
Anaemia; 
neutropenia 
Experimental 
in the united 
states and 
Canada 
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Anticopper therapy must be life long. With treatment, liver function usually 
recovers after about a year, although residual liver damage is usually present. 
Neurologic and psychiatric symptoms usually improve between 6 and 24 months 
of treatment.  
Table 4:Drugs used in the treatment of Wilson disease 
DISEASE STATUS FIRST CHOICE SECOND CHOICE 
Initial hepatic  
     Hepatitis or cirrhosis 
without decompensation 
Zinc Trientine 
Hepatic decompensation 
Mild 
Moderate  
Severe 
 
Trientine and Zinc 
Trientine and Zinc 
Hepatic transplantation 
 
Penicillamine and Zinc 
Hepatic transplantation 
Trientine and Zinc 
Initial psychiatric/ 
neurologic 
Tetrathiomolybdate  and 
Zinc 
Trientine and Zinc 
Maintanence Zinc Trientine 
Presymptomatic Zinc Trientine 
Pediatric  Zinc Trientine 
Pregnant Zinc Trientine 
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Diet 
Patients should generally avoid eating foods with a high copper content 
such as liver, chocolate, nuts, mushrooms, legumes and shellfish (especially 
lobster). Drinking water from atypical sources (e.g., well water) should be 
analyzed for copper content and replaced with purified water if the copper content 
is greater than 0.2 parts per million. 
 
Monitoring Anticopper Therapy   
When first using trientine or penicillamine, it is necessary to monitor for 
drug toxicity, particularly bone marrow suppression and proteinuria. Complete 
blood counts, standard biochemical profiles, and a urinalysis should be performed 
at weekly intervals for a month, then at 2-weekly intervals for 2 to 3 months, then 
at monthly intervals for 3 or 4 months, and at 4- to 6-monthly intervals thereafter.  
The anticopper effects of trientine and penicillamine can be monitored by 
following 24-h "free" serum copper. Changes in urine copper are more difficult to 
interpret because excretion reflects the effect of the drug, as well as body loading 
with copper. Free serum copper is calculated by subtracting the ceruloplasmin 
copper from the total serum copper. Each 10 mg/dL of ceruloplasmin contributes 
0.5 µmol/L (3.0 µg/dL) of serum copper. The normal free copper value is 1.6 to 
2.4 µmol/L (10 to 15 µg/dL), and it often is as high as 7.9 µmol/L (50 µg/dL) in 
untreated Wilson disease. With treatment, free copper should be  <3.9 µmol/L 
(<25 µg/dL).  
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Zinc treatment does not require blood or urine monitoring for toxicity. Its 
only significant side effect is gastric burning or nausea in about 10% of patients, 
usually with the first morning dose. This can be mitigated by taking the first dose 
an hour after breakfast or taking the zinc with a small amount of protein. Because 
zinc mainly affects stool copper, 24-h urine copper can be used to reflect body 
loading. The typical value in untreated symptomatic patients is >3.1 µmol (>200 
µg) per 24 h. This level should decrease during the first 1 to 2 years of therapy to 
<2.0 µmol (<125 µg) per 24 h. A normal value [0.3 to 0.8 µmol (20 to 50 µg)] is 
rarely reached during the first decade of therapy and should raise concern about 
over treatment (copper deficiency), the first sign of which is anemia and/or 
leukopenia. 
Surgical Care:  
• The use of surgical decompression or transjugular intrahepatic shunting 
(TIPS) in the treatment of portal hypertension is reserved for individuals 
with recurrent or uncontrolled variceal bleeding that is unresponsive to 
standard conservative measures. 
• Orthotopic liver transplantation is a potentially curative treatment of 
Wilson’s disease. 
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o Transplantation is primarily reserved for treatment of patients with 
fulminant liver failure or end-stage liver disease, which progresses 
despite chelation therapy. 
o The selection of patients for transplantation may be facilitated by 
determination of a prognostic index, which is based on the degree of 
abnormality of serum aspartate aminotransferase, bilirubin, and 
prothrombin time and appears to accurately predict a fatal or 
nonfatal outcome. 
o In the absence of severe hepatic disease, liver transplantation is 
generally not recommended for treatment of refractory extrahepatic 
manifestations. 
Prognosis:  
Table 5: Prognostic Index of NAZER in Fulminant Wilsonian Hepatitis  
Score (in points) Laboratory 
measurement 
Normal 
value 
0 1 2 3 4 
Serum 
bilirubin 
0.2 – 1.2 
mg/dl 
<5.8 5.8-8.8 8.8-11.7 11.7-
17.5 
>17.5 
Serum 
aspartate 
transaminase 
10-35 
IU/L 
<100 100-150 151-200 201-300 >300 
Prolongation 
of 
prothrombin 
time 
(seconds) 
- <4 4-8 9-12 13-20 >20 
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• Patients with a prognostic index (i.e., score) of 10 or greater should be 
considered immediately for liver transplantation. All patients who exceeded 
this score died within 2 months of diagnosis despite the institution of 
appropriate medical therapy. 
• Prognosis after liver transplantation is relatively good. In a study involving 
55 patients with Wilson disease who underwent hepatic transplantation, the 
1-year survival rate was 79% and the overall survival rate was 72% at 3 
months to 20 years. 
• In view of the social and economic implications and the occurrence of 
Wilson disease among family members, it is essential to look/ search for 
Wilson disease as early as possible and provide them appropriate treatment 
to delay the progression. 
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Materials and Methods 
Study Design  : Prospective observational study 
Setting   : Govt. Rajaji Hospital, Madurai 
Collaborating 
  Departments           :          Department of Neurology & Department of Medicine 
Period of study : August 2004 to August 2006 
Ethical clearance : Ethical committee approved the methodology of the study  
                                             and the copy was enclosed in annexure I 
Consent   : Consent was obtained from all the patients considered for the  
                                             current study. 
Financial support : This project did not receive funds from any national  
    National organization/ charitable agencies. 
Conflict of interest : Nil  
Inclusion criteria  
1) Patients belonging to the age group of 5-50 yrs with one or other 
neurological manifestations in  the form of 
 Extra pyramidal features like tremors, choreoathetosis, dystonia 
and akinetic rigid syndromes 
 Cerebellar manifestations in the form of intention tremors, ataxia, 
dysarthria, etc. 
 Neuropsychiatric manifestations  
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Patients with the above mentioned manifestations who had  
1. Kayser Fleischer rings and 
2. decreased serum ceruloplasmin (<20 mg/dl) 
were taken  up for the study. 
Exclusion criteria 
  The exclusion criteria included 
1) Patients with the above neurological manifestations but who did not 
satisfy the criteria for the diagnosis of Wilson disease. 
2) Patient not willing to cooperate for the evaluation. 
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METHODS 
Socio-demographic and clinical data were elicited from the patients. 
Laboratory results were obtained and recorded in a pro forma (enclosed in 
annexure II). 
I. Socio demographic data:  
a) Age        
b) Sex     
c) Locality     
d) Occupation        
e) Family history and symptoms among family members 
II. Clinical data 
a) Height      
b) Weight      
c) Pulse rate      
d) Blood pressure      
e) Clinical history and examination      
f) Slit lamp examination 
III. Laboratory data 
a) Complete hemogram 
b) Blood sugar & serum electrolytes 
c) Urine examination & renal function tests 
d) Liver function tests 
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e) Serum ceruloplasmin 
f) Electrocardiogram 
IV. Imaging studies 
a) Chest x-ray PA view 
b) X-ray of joints in selected cases 
c) Ultrasound examination of abdomen 
d) CT &/ MRI imaging of the brain in selected cases 
 
 Hemoglobin was measured using Sahli’s hemoglobinometer.         
Total count was carried out using hemocytomer, differential count carried 
out using Leishman’s stain and platelet count was counted manually by using  
cresyl violet staining. 
Urine analysis was completed by adopting standard bedside procedure.                                    
Blood sugar, blood urea, serum creatinine and serum electrolytes were 
estimated using ERBA XL 300 automated analyzer. 
ECG: 12 lead ECG was taken in all the patients 
X-ray Chest: PA view was taken in a radiation dosage of 0.02mSv. 
Serum ceruloplasmin was determined using the oxidation method and 
values < 20 mg/dl were taken as abnormal. 
Ultrasound examination of abdomen was done in all patients. 
Computerized tomography of brain and magnetic resonance imaging of 
brain were done in selected patients. 
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Limitations of the study 
1) Due to technical reasons all patients could not be investigated with free 
copper and urinary copper levels. 
2) Considering the invasive nature, ethical committee clearance did not 
permit to perform liver biopsy to assess the copper levels in liver tissue. 
3) Family members could not be screened as most of the patients’ relatives 
did not turn up for the screening of the disease due to socio cultural 
implications of the progressive nature of the disease and the probable 
familial occurrence. 
4) Due to socio-economic constraints most of the patients could not be 
followed up.  
5) Genetic studies could not be done. 
6) Specialized statistical analysis could not be applied in view of the small 
number of cases reported to the tertiary care centre over a period of 24 
months. 
BIAS : 
1) Selection bias – the selection of cases of Wilson disease was limited 
to those with neurological manifestation only. 
2) Recall bias – symptomatology at onset of the disease was considered 
as reported by the patient or their family members of relatives. 
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RESULTS 
 A total of 64 patients who had one or other forms of extrapyramidal 
manifestations with/without cerebellar, with/without neuropsychiatric 
manifestations were screened for the Wilson disease.  The diagnosis was 
ascertained in 19 patients.  Thus the prevalence of Wilson disease among those 
with extrapyramidal manifestations/cerebellar was 29.5% during the study period.  
These patients have been analyzed in detail. 
DISTRIBUTION OF CASES ACCORDING TO AGE AND GENDER 
 Among the 19 patients, there were 8 males and 11 females. 
Table 6: Comparision of age group and gender  
PATIENTS AGE GROUP 
(in years) MALE FEMALE TOTAL 
0-10 0 - 1 9.1% 1 5.3 
11-20 5 62.5% 8 72.7% 13 68.4 
21-30 2 25% 1 9.1% 3 15.8 
31-40 1 12.5% 0 - 1 5.3 
>40 0 - 1 9.1% 1 5.3 
TOTAL 8 100 11 100 19 100 
MEAN 20.13 18.27 19.05 
SD 9.37 9.69 9.34 
‘p’ 0.8038 
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 The youngest one to present was a 8 year old girl and the older one was a 
45 year old male, both had neurological symptoms lasting months before the 
hospitalization.  The mean age and SD of the study group among males and 
females was 20.3±9.4 and 18.3±9.7 years respectively. 
 The age of presentation was not significant with reference to gender.  
 Overall the average age of presentation has been determined to be 19.05 
years with majority of patients falling in the 2nd decade group. 
 
POSITIVE FAMILY HISTORY & CONSANGUINITY IN STUDY SUBJECTS 
 Out of 19 subjects 12 were born out of consanguineous marriage. 
 History of family members with the disease was obtained in 9 out of 19 
subjects only. 
 Family members could not be screened as they were unwilling for 
screening. 
 
DISTRIBUTION OF CASES ACCORDING TO DURATION OF SYMPTOMS 
 Duration of symptoms before the 1st presentation of all patients were 
obtained either from the patient or parents or relatives and it varied from 1 month 
to 5 years.  The period of symptoms are displayed below in Table 7. 
 Mean duration of symptoms was 20.5 months. 
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Table 7: Age group in relation to duration of symptoms 
AGE GROUP 
MEAN 
(in months) 
SD 
0-10 6.1 - 
11-20 15.1 15.16 
21-30 30.42 18.25 
31-40 36.5 - 
>40 60.83 - 
TOTAL 20.58 18.54 
‘p’ 0.1573 
The younger the patient the duration was less. 
 The gender variation in the duration of symptomatology had been analyzed 
Average duration of symptoms in male patients was 18.47 months and it was 
22.09 months among females.  However, it was not significant statistically 
(p=0.8352).  The details are provided in Table 8. 
Table 8: Duration of symptoms in relation to gender 
DURATION OF SYMPTOMS 
(in months) 
GENDER 
MEAN SD 
MALE 18.48 12.01 
FEMALE 22.01 22.62 
‘p’ 0.8352 
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DISTRIBUTION OF CASES ACCORDING TO THE SYMPTOMATOLOGY 
The pattern of presentation was analyzed and categorized into four distinct 
types based upon the predominant symptoms.   The patterns of presentation were 
compared with the age group, gender and the duration of symptoms. Although the 
study subjects were categorized into 4 groups based on the neurological findings 
there was considerable overlap of clinical features in all the patients. 
 The results are presented in the Table 9. 
Table 9: Age group and pattern of neurological manifestation 
AGE (in years) PATTERN OF 
PRESENTATION* MEAN SD 
PARKINSONIAN(6) 19.2 13.2 
PSEUDOSCLEROTIC(8) 22.6 7.7 
DYSTONIC(3) 12.3 1.2 
CHOREIC(2) 14.5 2.1 
‘p’ 0.0345 
*Welshe (1984) 
 
 The majority of the patients presented with tremors which characteristically 
worsened on action and cerebellar symptoms were observed among these patients. 
 Choreic movements were noticed only in 2 cases and that too in upper 
limbs. There was significant correlation (p=0.03) between the age and the pattern 
of presentation.  
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Duration of symptoms varied from 1.9 months to 26.6 months in various patterns 
of neurological manifestation which are given in Table 10. 
Table 10: Duration of symptoms and pattern of neurological manifestation 
DURATION OF SYMPTOMS (in months) PATTERN OF 
PRESENTATION MEAN SD 
PARKINSONIAN 18.5  21.26 
PSEUDOSCLEROTIC 26.62 17.5 
DYSTONIC 1.94 1.78 
CHOREIC 15.2 12.9 
 
 However, there was no correlation could be made between the pattern of 
presentation and duration of symptoms. 
 Pattern of neurological manifestation in relation to gender is provided in 
Table 11 below. 
Table 11: Pattern of presentation in relation to gender 
GENDER 
MALE FEMALE 
PATTERN OF 
PRESENTATION 
No. % No. % 
PARKINSONIAN 3 50 3 50 
PSEUDOSCLEROTIC 3 37.5 5 62.5 
DYSTONIC - - 3 100 
CHOREIC 2 100 - - 
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HEPATIC MANIFESTATIONS 
The hepatic manifestations of the disease was considered when all or any 
one of the following were present 
1) A positive history of jaundice in the past or at the time or presentation 
or 
2) Symptoms suggestive of chronic liver disease in the past or at the time or 
presentation 
or 
3) Clinical findings suggestive of liver disease 
or 
4) Investigations supporting hepatic involvement. 
 
The results of the analysis were compared with other parameters of the 
patients. 
Table 12: Hepatic disease in relation to gender 
GENDER 
MALE FEMALE 
HEPATIC 
MANIFESTATION 
No. % No. % 
PRESENT(8) 5 62.5 3 37.5 
NOT PRESENT(11) 3 27.3 8 72.7 
‘p’ 0.1438 
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 Out of the total 8 patients who had hepatic involvement 6 patients were 
proved to be cirrhotic with clinical examination and/ investigations, 2 patients had 
previous history of jaundice which could be attributed to the disease process 
manifesting as jaundice during childhood but went undiagnosed.  
Table 13: Duration of neurological symptoms and hepatic disease 
DURATION OF SYMPTOMS (in months) HEPATIC 
MANIFESTATION MEAN SD 
PRESENT 15.94 14.29 
NOT PRESENT 24.28 21.12 
‘p’ 0.5057 
 
 The average duration of symptoms with hepatic disease was 15.94 months 
and without hepatic disease was 23.28 months. 
Table 14: Age and hepatic disease 
AGE (in years) HEPATIC 
MANIFESTATION MEAN SD 
PRESENT 18.3 9.3 
NOT PRESENT 19.6 9.8 
‘p’ 0.5076 
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There was no significant correlation noted between the age and incidence of 
the hepatic disease in these patients.  There was no correlation noted between sex 
and the incidence of hepatic disease, similarly with duration of neurological 
symptoms and the incidence of hepatic disease.  
All the patients who did not have hepatic manifestations with the above 
criteria were considered to have hepatic disease in a sub clinical form and as liver 
biopsy could not be done for these patients it is wise to consider them to be having 
liver disease until proved otherwise. 
 
NEUROLOGICAL PATTERN AND HEPATIC MANIFESTATION 
 The correlation of the neurological pattern with the hepatic manifestation of 
the disease  were analyzed. 
Table 15: Pattern of neurological disease and hepatic disease in study subjects 
HEPATIC MANIFESTATION 
PRESENT ABSENT 
PATTERN OF 
PRESENTATION 
No. % No. % 
PARKINSONIAN 3 50 3 50 
PSEUDOSCLEROTIC 2 25 6 75 
DYSTONIC 1 33.3 2 66.7 
CHOREIC 2 100 0 - 
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There was no significant difference in the groups compared except with the 
majority of pseudosclerotic patients not having hepatic manifestations. 
• Stigmata of chronic liver disease were observed in 3 patients (1-
pseudosclerotic, 2-choreic group) however one had evidence of 
hepatic decompensation at the time of presentation. 
• Splenomegaly of mild to moderate degree was observed in 4 
patients. 
• Hepatomegaly of mild degree was observed in only one patient. 
• Liver span was reduced in 3 patients. 
 
PSYCHIATRIC MANIFESTATIONS OF THE DISEASE 
 The number of patients with psychiatric manifestations either preceding or 
coexisting with the neurological symptoms were analyzed which was noticed in 9 
patients only. 
Baseline data of both group of patients were analyzed and compared. 
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Table 16: Comparision of psychiatric manifestation with age, sex and duration of 
neurological disease 
PSYCHIATRIC MANIFESTATION 
PRESENT ABSENT 
VARIABLE 
No. % No. % 
‘p’ 
1) SEX 
MALE 
FEMALE 
 
4 
5 
 
50 
45.5 
 
4 
6 
 
50 
54.5 
 
0.605 
2) AGE (in years) 
MEAN 
SD 
 
19 
10 
 
19.1 
9.3 
 
0.8059 
3) DURATION OF    
SYMPTOMS (in months) 
MEAN 
SD 
 
 
19.24 
19.60 
 
 
21.78 
18.51 
 
 
0.7421 
 
Both the groups had similar features except for the female predominance in 
those without psychiatric symptoms but there was no statistical significance in the 
variables (age, duration of neurological symptoms and sex) and the psychiatric 
manifestation when compared. 
Three out of nine patients had psychiatric symptoms preceding the 
neurological manifestation by a few years. 
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Majority of the patients exhibited one or other symptoms which were in the 
form of  
1) personality changes – irritability, emotional lability, extreme anger, 
decreased threshold and decreased ability to control it and 
occasional aggression. 
2) Psychosis 
3) Cognitive changes – intellectual decline, detoriating school 
performance 
4) Depression 
The results are provided here in the Table 16 below 
Table 17: Pattern of psychiatric manifestation 
Pattern of psychiatric manifestation Number of patients 
Personality changes 4 
Psychosis 3 
Cognitive changes 3 
Depression 1 
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To study whether the pattern of neurological symptoms had any correlation 
with the psychiatric manifestation, both the groups were compared and analyzed 
and the details are provided in Table 17 below. 
Table 18: Psychiatric manifestation and the pattern of neurological manifestation 
PSYCHIATRIC  MANIFESTATION 
PRESENT ABSENT 
PATTERN OF 
PRESENTATION 
No. % No. % 
PARKINSONIAN 5 83.3 1 16.7 
PSEUDOSCLEROTIC 2 25 6 75 
DYSTONIC 0 - 3 100 
CHOREIC 2 100 0 - 
 
 Psychiatric manifestation in the form of personality changes were observed 
in the majority of parkinsonian patients for whom cognitive assessment was 
difficult.  Psychiatric manifestations were absent in the majority of pseudosclerotic 
patients and nil in the dystonic group. 
 
OTHER MANIFESTATIONS OF THE PATIENTS 
Autonomic symptoms 
 Out of 19 only one patient had autonomic symptoms in the form of profuse 
sweating involving all over the body which preceded the neurological 
manifestation (parkinsonian group). 
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• One episode of seizure of generalized tonic clonic nature was described by 
one patient (female aged 17 years) when the patient was 2 years of age and 
did not have further episodes.  
• One patient had clinical presentation as of an acute encephalopathy when 
she was ten years old. 
• Anosmia was complained by one patient and was confirmed on clinical 
examination. 
Bleeding manifestations 
 Bleeding manifestation in the form of epistaxis and gum bleeding were 
observed apart from the gastrointestinal bleed due to varices which was observed 
in only one patient. Number of patients who had epistaxis/bleeding gums were 5 
eventhough all the patients had a normal platelet count, bleeding time and clotting 
time.  Interestingly four out of five patients had evidence of liver disease. 
Musculoskeletal symptoms 
 Patients were observed for any musculoskeltal manifestations in the form of 
joint pains, joint deformities, osteoarthritic changes in the joints, etc. 
 Six  patients had symptoms of joint pain(4 in the parkinsonian group & 2 in 
the pseudosclerotic group) which necessitated analgesics for pain management.  
The knee joint was the most common joint involved joint.  
 One patient (17 years of age) had osteoarthritic changes involving the 
major joints of both lower limb and also the small joints of both upper limb in a 
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symmetrical manner.  She also had features of secondary fanconi’s syndrome due 
to copper deposition in the proximal tubular epithelium of kidney. 
Menstrual disturbances 
 Out of 11 female patients 7 attained menarche, out of which 3 had delayed 
menarche ( average = 16 yrs). 
 Five patients had regular menstrual cycles and 2 had irregular cycles. 
 Only one patient got married but did not have any child. 
Other symptoms 
• Night blindness was complained in 2 patients both had hepatic 
disease. 
GENERAL EXAMINATION FINDINGS IN STUDY SUBJECTS 
• All the study subjects had bilateral Kayser Fleischer ring visible 
without the aid of Slit lamp. 
• Two patients had extensive tinea versicolor over the neck & trunk. 
• Blue nails was observed in two patients. 
• Vital data finding among the study subjects were normal. 
• Features of osteoarthritic changes in small joints of both hands were 
observed in one patient with fanconi’s syndrome. 
OPHTHALMOLOGICAL FINDINGS IN STUDY SUBJECTS 
• All patients were confirmed to have corneal rings by Slit lamp 
examination. 
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• Other ophthalmological findings include, 
o Sunflower cataract was observed in only one patient. 
o Subcapsular punctate cataract was observed in two patients. 
 
SERUM CERULOPLASMIN IN STUDY SUBJECTS 
 All patients were investigated for serum ceruloplasmin and ranged from 10 
mg/dl to 26 mg/dl,   
 The average serum ceruloplasmin of the patients was 15.04 mg/dl with 
values as low as <10 mg/dl observed. 
There was no gender variation in the serum ceruloplasmin levels. 
The values of the study subjects are provided in the tables given below. 
Table 19: Serum ceruloplasmin levels in different age groups 
SERUM CERULOPLASMIN(mg/dl) 
AGE GROUP 
MEAN SD 
0-10 10.0 - 
11-20 14.02 4.71 
21-30 16.7 0.96 
31-40 26 - 
>40 17.4 - 
‘p’ 0.1531 
MALE 14.15 5.97 
FEMALE 15.69 4.25 
‘p’ 0.455 
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 There was no significant correlation when statistically analyzing the age 
and the serum ceruloplasmin levels. 
 The higher serum ceruloplasmin level observed in one patient had evidence 
of hepatic decompensation at the time of presentation which might have falsely 
elevated the ceruloplasmin level.   
Table 20: Comparision of serum ceruloplasmin and pattern of neurological illness 
SERUM CERULOPLASMIN (mg/dl) PATTERN OF 
PRESENTATION MEAN SD 
PARKINSONIAN 12.3 2.89 
PSEUDOSCLEROTIC 18.48 4.66 
DYSTONIC 14.8 3.97 
CHOREIC 9.9 4.8 
‘p’ 0.03 
 
 There was significant correlation (p=0.03) and the pattern of neurological 
manifestation with low values noted in the choreic and Parkinson group and higher 
ceruloplasmin values obtained in the pseudosclerotic group. 
• Urine examination for all subjects was nil contributory but for 2 subjects 
who had abnormal urine examination out of which one had features of 
fanconi’s syndrome and the other had only glycosuria, mild albuminuria 
and screening for aminoaciduria was negative. 
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• Hemoglobin, total count and differential count of the patients were within 
normal limits.  There was no evidence of hemolysis in the patients during 
the study period, however they were not investigated with haptoglobulin 
levels. 
• Biochemical evidence of hepatic decompensation was present only in one 
patient, the rest had a normal Liver function profile except for a decreased 
serum albumin (<3.5g/dl) in 5 patients and elevated SGPT in 2 patients.   
• Serum alkaline phosphatase was found elevated in 4 patients out of which 
one had evidence of secondary hyperparathyroidism as a part of fanconi’s 
syndrome for others the cause was undetermined. 
• Other biochemical parameters like blood sugar, blood urea and serum 
creatinine were within normal limits in all the study subjects. 
IMAGING STUDIES IN THE STUDY SUBJECTS 
• Ultrasound imaging of the liver showed altered echopattern of liver 
and decreased size of the liver in 6 patients. 
• Chest X-ray of all the patients were within normal limits. 
• X-ray of knee joint taken for those with symptomatic joint 
manifestations showed osteoarthritic changes 3 patients.  Diffuse 
osteopenia was present in one patient who had fanconi’s syndrome. 
• CT was done only in 2 subjects who had bilateral hypodensities in 
basal ganglia. 
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• MR imaging was done in only one subject who had bilateral 
hypointense signal changes in T1W & hyperintense changes in T2 & 
FLAIR in thalamus, putamen, cerebral peduncles, midbrain & pons. 
TREATMENT RESPONSE IN STUDY SUBJECTS 
• Out of 19 patients only 6 patients turned up for follow up and so the clinical 
response of those 6 patients to treatment was assessed. 
• Two of the pseudosclerotic group showed a good response to                      
d-penicillamine therapy and were symptom free by about 8 months of 
therapy. 
• Two other patients of the parkinsonian group did not show remarkable 
improvement in symptom control in the short term follow up for 6 months. 
• Two other patients showed detoriation of clinical condition after d-
penicillamine therapy and discontinued therapy.  They were alternatively 
treated with zinc. 
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DISCUSSION 
 Neurological manifestations is the second most common presentation of 
Wilson disease.  Although hepatic manifestations is the most common 
presentation, adults with Wilson disease have predominantly neurological 
manifestations. 
The onset of neurological symptoms is usually in the second and less often 
in the third decade, rarely beyond that time.  Half of patients are symptomatic by 
age 15, but exceptionally patients present at an early or later age group. 43  In our 
study majority of patients (68.4%) present in the second decade with a mean age 
of 19 years.  The youngest patient was a 8 year old girl who had neurological 
symptoms lasting for many months before 1st presentation.  The oldest patient in 
our study was a 45 year old woman who had  symptoms lasting few months before 
1st presentation. 
There is no gender variation in the neurological or any other form of 
manifestation in Wilson disease except for a slight increased frequency of 
fulminant hepatic failure in females.  In our study, females outnumber males but 
still they do not show statistical significance when compared individually with the 
age group.  Similarly there is no correlation between gender and the age of 
presentation understating the autosomal recessive nature of the disease. 
The first neurological manifestations are most often extrapyramidal with a 
proclivity to affect the oropharyngeal musculature. 43 In our study most of the 
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patients had tremors either in the form of action/intention/resting tremors to start 
with later increasing in severity to affect the truncal and bulbar muscles.  
However, all patients exhibited some form of extrapyramidal manifestations in the 
form of dystonia, chorea, resting tremors, parkinsonian features, etc. 
predominating in atleast 60% of patients. 
The duration of symptoms at first presentation has been compared with 
many variables.  Two of our patients who had dystonia presented early (one 
month) when compared with the duration of symptoms of other patterns of the 
disease which averaged more than 21 months.  There is no significant correlation 
in the duration of symptoms and the patterns of the presentation.  The nature of the 
disability produced by the dystonia would have made the patients present with a 
short duration of symptoms.  Similarly there was no gender influence of the 
symptomatology of the disease, but considering the social influence on female sex 
they may come to hospital late with the symptoms. 
The age of the patient here showed a statistical significance (p=0.03) when 
compared with the pattern of presentation with majority of pseudosclerotic 
patients presenting at a later age (mean age = 22.6).  The average age for other 
patterns of the disease was around 15 years.  This observation states the influence 
of age on the pattern of presentation and needs further large scale studies to prove 
such an association. 
Although the liver is the first organ to suffer the toxicity of copper 
accumulation not all patients have manifestations out of liver disease.  Subclinical 
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evidence of liver injury due to copper accumulation have been observed, so every 
other patient without clinical evidence of liver disease is said to have subclinical 
liver damage until proved otherwise.  In our study 8 patients had evidence of liver 
disease (approx. 42%) which preceded the neurological manifestation most of the 
times. 
The influence of the hepatic disease on the neurological manifestation of 
the disease has been studied and analyzed.  The results show no such statistical 
correlation between the symptomatology and  concomitant hepatic disease. 
Neuropsychiatric manifestations are common which begins early or present 
subtly along with the neurological symptoms.  Exceptionally, an abnormality of 
behavior or a gradual impairment of intellectual function precedes other 
neurologic signs by a year or more. 43  In our study 9 out of 19 patients had 
psychiatric symptoms amounting to approximately 50% of patients. 
In our study 3 patients had psychiatric symptoms which preceded 
neurological manifestations by a year.  Other patients had psychiatric 
manifestations observed along with neurological symptoms at the time of 
presentation.  They were mostly in the form of  personality changes and cognitive 
dysfunction. 
The pattern of psychiatric symptoms were correlated with the neurological 
pattern and analysis revealed that personality changes were seen in most of the 
patients of parkinsonian group and were found to be decreased in frequency in 
pseudosclerotic group. 
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No other correlation of statistical significance was observed when 
comparing the psychiatric group with other variables. 
Kayser-Fleischer rings are present invariably when there are neurological 
manifestations.  A slit lamp examination may be necessary for their early detection 
particularly in brown-eyed patients, but in the majority of patients with 
neurological signs the rings can be visualized with the naked eye or with the aid of 
an indirect ophthalmoscope focused on the limbus. 43  Kayser-Fleischer ring was 
present in all patients in our study seen even with the naked eye confirmed by slit 
lamp examination.  Three of our patients had cataract.  One patient had sunflower 
cataract,  the two others had posterior subcapsular cataracts. 
Symptomatic joint disease, which occurs in 25-50% of patients,44,45 usually 
presents late in course of the disease, frequently after 20 years of age; although 
occasionally osteoarthritis may be the initial manifestation.46,47,48 
The general radiographic features of Wilson Disease consists of osteopenia 
and arthropathy. The arthropathy of Wilson disease observed on radiographic 
evaluation in 3/4th of all patients is a degenerative process that resembles 
premature osteoarthritis.44,45,49,50,51 The arthropathy generally involve the spine, 
large appendicular joints such as wrist, elbow, shoulder, hip, knee, and 
metacarpophalangeal joints, associated with periarticular osteopenia. Radiologic 
studies reveal typical degenerative changes including osteophytes, sclerosis, 
subchondral pseudocysts, and bone fragmentation. 
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 In our study musculoskeletal manifestations (40% ) were in the form of 
joint pain affecting knee joint in the majority of patients.  One patient had 
arthralgia affecting multiple joints with radiological findings suggestive of 
osteoarthritic changes.  
One patient presented with joint pain and deformities affecting the distal 
interphalangeal joints of both hands who had radiologically diffuse osteopenia and 
arthritic changes.  The patient was found to have features of fanconi’s syndrome 
with elevated alkaline phosphatase. 
Other manifestations of Wilson include autonomic symptoms, which was 
present in one of our patient.  Symptoms of bleeding in the form of epistaxis and 
gum bleeding was present in 26.3 % of patients, majority of them had liver disease 
which could explain the bleeding tendency. 
Menstrual irregularities were noted in 2 of our patients out of 7 female 
patients who attained menarche.  Three out of them had delayed onset of 
menarche.  Menstrual irregularities has been attributed to endocrine disturbances 
secondary to disease process affecting the endocrine glands. 
Hemolysis was not evidenced in any of our patients who had normal 
peripheral smear morphology and a normal hemoglobin values.  However further 
investigations like serum haptoglobulin and others had not been done to assess the 
hemolysis. 
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Serum ceruloplasmin was measured in all patients and the average was 
15.04 mg/dl.  There was no positive correlation between the serum ceruloplasmin 
and the other variables like age, sex and duration of symptoms.   
However, there was a significant correlation between serum ceruloplasmin 
levels and the pattern of neurological manifestation (p=0.03)  with lesser values 
obtained in the parkinsonian and choreic group and higher values obtained in the 
pseudosclerotic group.   
Treatment response was assessed only in 6 patients who had a regular 
follow up for upto 8 months.  Two patients of the pseudosclerotic group showed 
remarkable symptom control and almost free of symptoms by 6-8 months.  Two 
patients of the parkinsonian group did not show much of improvement even after 
prolonged therapy for 8 months.  Two patients developed worsening of 
neurological symptoms after D-penicillamine therapy and was discontinued and 
started on zinc.  But in majority of patients the reason for discontinuation was the 
high cost of drugs which they were not affordable and the slow improvement in 
symptomatology which makes them discontinue the medications. 
Strength of the study: 
¾ Rigid criteria to assess those with neurological presentation 
¾ All of them who satisfied the rigid criteria were studied over a 
period of 24 months. 
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CONCLUSION 
1. The prevalence of Wilson disease with neurological manifestations at a 
neurology centre in tertiary care level was 0.4% 
2. Among them those with extrapyramidal with or without cerebellar with 
or without  neuropsychiatric manifestations in patients of the age group 
5-50 years was around 29.5% 
3. The most common age group of presentation is in the second decade. 
4. Age of onset, duration of symptoms and the pattern of neurological 
manifestation was independent of gender. 
5. Most common neurological manifestation were in the form of 
extrapyramidal symptoms. 
6. Most common pattern of neurological manifestation were in the form of 
tremors (pseudosclerotic group), the second being parkinsonism. 
7. Majority of pseudosclerotic patients presented later when compared to 
younger age of presentation in dystonic/choreic group. 
8. The pattern of neurological manifestation were independent of the status 
of liver. 
9. Psychiatric manifestation were observed in half of patients with 
personality disorders predominating in the parkinsonian group. 
10. Serum ceruloplasmin had a significant correlation with the pattern of 
neurological manifestation with higher values obtained in 
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pseudosclerotic group and lesser values obtained in parkinsonian and 
dystonic group. 
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AREAS OF FURTHER WORK/RECOMMENDATION 
¾ To determine the incidence among population and disease burden proper 
documentation of all cases and through effective screening of all 
asymptomatic carriers of the abnormal gene. 
¾ It is recommended to develop a disease registry at a higher tertiary care 
centre with proper hierarchical referral system. 
¾ To correlate the phenotype of the patients with the genotypes. 
¾ To study the pattern of the Wilson disease in Indian patients in a large scale 
prospective study and compare with the western world to elicit further 
differences in the presentation, severity of the disease, phenotype and 
genotype of the disease and the treatment response. 
¾ To develop measures to decrease the incidence, develop less expensive 
methods for diagnosis, prevent morbidity by early identification and 
effective treatment and importance of genetic counseling.  
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SUMMARY 
 
 Wilson disease is an autosomal recessive disorder characterized by 
degenerative changes in the brain, liver disease, and Kayser-Fleischer rings in the 
cornea. The disease has protean manifestations.  It is fatal if untreated; requiring 
early diagnosis and effective treatment.  Neurological manifestations arising out of 
Wilson disease is an important cause for the morbidity and mortality of the 
disease.  Prompt identification of subtle neurological symptoms during early 
stages is important.  As the disease advances, most of the symptoms do not 
completely resolve even with our effective treatment. 
 An attempt has been made here to study the Wilson disease through 
nervous system.  The study was conducted over a period of 2 years screening for 
all the patients attending the neurology clinic with either one or the other 
neurological manifestations classical for Wilson disease.  Nineteen patients 
selected for the study were divided into 4 major groups based on the predominant 
symptoms – parkinsonian, pseudosclerotic, dystonic and choreic.  The patients 
were analyzed with respect to age, gender, duration of neurological symptoms, 
hepatic disease, psychiatric manifestations and serum ceruloplasmin level. 
 The study concluded that Wilson disease constituted  approximately 30% of 
patients presenting with one or other symptoms in the form of extrapyramidal, 
cerebellar &/ psychiatric manifestations. 
Extrapyramidal symptoms were the most common manifestation, with 
majority of patients presenting in the second decade.  Most of the pseudosclerotic 
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patients present at a later age when compared with younger age of presentation 
seen with choreic/dystonic group.  Family history was strong in 50% of patients 
with high rates of consanguinity observed.  Hepatic manifestations of the disease 
were independent of the neurological manifestation.  Almost half of patients 
exhibited psychiatric symptoms.   
 Serum ceruloplasmin levels were low in the dystonic and choreic group 
whereas higher levels were seen with the pseudosclerotic group which was 
statistically significant. 
 The study identified early manifestations in the form of tremors 
predominating in most of the patients.  Such patients present early with detoriation 
in handwriting, slowness of activities and decline in school performance.  It is not 
only the duty of the physician to appreciate such earlier symptoms but the duty of 
school teacher to identify them early and refer them timely to an appropriate 
health care system.  Teachers and parents have to be educated for the same. 
 Apart from screening of family members using the newer molecular and 
genetic testing, genetic counseling is vital which helps to decrease the incidence of 
the disease in the community. 
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APPENDIX II 
 
PROFORMA 
 
Period of study : 
Patient number : 
Name   :  
In patient number : 
Age at presentation : 
Sex    : 
Contact address : 
 
 
 
 
Marital status : 
Occupation     : 
Income  :  
Referred from : 
 
 
Chief complaints 
  
 
 
 
 
 
 
 
 
History of presenting complaints 
 
 
 
 
 
 
 
 
 
 
 
Past history 
 
 
 
 
 
 
Family history 
 
 
 
No. of siblings/children  
 
Whether born out of consanguineous marriage:         
 
Prenatal/natal/postnatal history: 
 
Developmental history: 
 
Immunization history: 
 
Drug/trt. History: 
Clinical examination findings 
General examination: 
Built - 
Nourishment  - 
Cyanosis - clubbing - jaundice - pallor - pedal edema    -  
Lymphadenopathy - 
Signs of liver cell failure - 
KF ring  
Vital signs 
Pulse -    temperature –  
BP-     RR –  
 
System examination 
 
 
Central nervous system 
 
 
 
Abdomen  
 
 
 
Cardiovascular system 
 
 
 
Respiratory system  
 
 
 
Clinical summary: 
 
 
 
Investigations  
General  
Complete hemogram 
 
Blood urea -    Blood sugar -   Serum creatinine-  
 
Serum electrolytes - 
 
Urine examination 
 
Chest X- ray   
 
ECG  
 
Liver function tests 
Bilirubin  
 Total  -  
 Direct - 
 Indirect-  
SGOT -  
SGPT -  
ALP –  
 
Serum proteins 
 Total -  
 Albumin -  
 Globulin -  
Serum ceruloplasmin -  
 
Ultrasound  
 
UGI scopy  
 
CT scan/ MRI 
 
Serum copper – free 
    Total 
Urinary copper (24 hour) 
 
Liver biopsy 
 
Specialists opinion: 
MGE opinion:  
 
Opthalmologist opinion: 
 
Psychiatrist opinion: 
 Neurologist opinion: 
 
ENT opinion:  
 
Treatment  
Date of starting treatment  
Clinical condition after starting treatment 
Follow up  
 
Medicine procured from 
Compliance of drugs 
Reason for discontinuation (if any) 
 
Financial constraints 
Prognosis : 
 
Alive/ dead : 
 
 
Cause of death : 
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